1
|
Fisher R, Pusztai L and Swanton C: Cancer
heterogeneity: Implications for targeted therapeutics. Br J Cancer.
108:479–485. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Graff BA, Kvinnsland Y, Skretting A and
Rofstad EK: Intratumour heterogeneity in the uptake of
macromolecular therapeutic agents in human melanoma xenografts. Br
J Cancer. 88:291–297. 2003. View Article : Google Scholar : PubMed/NCBI
|
3
|
Kim JH, Ko ES, Lim Y, Lee KS, Han BK, Ko
EY, Hahn SY and Nam SJ: Breast cancer heterogeneity: MR imaging
texture analysis and survival outcomes. Radiology. 282:665–675.
2017. View Article : Google Scholar : PubMed/NCBI
|
4
|
Beca F and Polyak K: Intratumor
heterogeneity in breast cancer. Adv Exp Med Biol. 882:169–189.
2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Aleskandarany MA, Green AR, Ashankyty I,
Elmouna A, Diez-Rodriguez M, Nolan CC, Ellis IO and Rakha EA:
Impact of intratumoural heterogeneity on the assessment of Ki67
expression in breast cancer. Breast Cancer Res Treat. 158:287–295.
2016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Suda K, Murakami I, Sakai K, Tomizawa K,
Mizuuchi H, Sato K, Nishio K and Mitsudomi T: Heterogeneity in
resistance mechanisms causes shorter duration of epidermal growth
factor receptor kinase inhibitor treatment in lung cancer. Lung
Cancer. 91:36–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Bashir U, Siddique MM, Mclean E, Goh V and
Cook GJ: Imaging heterogeneity in lung cancer: Techniques,
applications, and challenges. AJR Am J Roentgenol. 207:534–543.
2016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Obulkasim A, Ylstra B, van Essen HF,
Benner C, Stenning S, Langley R, Allum W, Cunningham D, Inam I,
Hewitt LC, et al: Reduced genomic tumor heterogeneity after
neoadjuvant chemotherapy is related to favorable outcome in
patients with esophageal adenocarcinoma. Oncotarget. 7:44084–44095.
2016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Cao W, Wu W, Yan M, Tian F, Liu HS, Wang
JW, Zhang QW, Li YJ and Li M: Multiregion sequencing reveals
intratumor heterogeneity in esophageal squamous cell carcinoma.
Zhonghua Zhong Liu Za Zhi. 38:660–666. 2016.(In Chinese).
PubMed/NCBI
|
10
|
Chen LQ, Hu CY, Ghadirian P and Duranceau
A: Early detection of esophageal squamous cell carcinoma and its
effects on therapy: An overview. Dis Esophagus. 12:161–167. 1999.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Schweigert M, Dubecz A and Stein HJ:
Oesophageal cancer-an overview. Nat Rev Gastroenterol Hepatol.
10:230–244. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Spalding K, Board R, Dawson T, Jenkinson
MD and Baker MJ: A review of novel analytical diagnostics for
liquid biopsies: Spectroscopic and spectrometric serum profiling of
primary and secondary brain tumors. Brain Behav. 6:e005022016.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Xie X, Jiang Y, Yuan Y, Wang P, Li X, Chen
F, Sun C, Zhao H, Zeng X, Jiang L, et al: MALDI imaging reveals
NCOA7 as a potential biomarker in oral squamous cell carcinoma
arising from oral submucous fibrosis. Oncotarget. 7:59987–60004.
2016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Potjer TP, Mertens BJ, Nicolardi S, van
der Burgt YE, Bonsing BA, Mesker WE, Tollenaar RA and Vasen HF:
Application of a serum protein signature for pancreatic cancer to
separate cases from controls in a pancreatic surveillance cohort.
Transl Oncol. 9:242–247. 2016. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ren J, Zhang D, Liu Y, Zhang R, Fang H,
Guo S, Zhou D, Zhang M, Xu Y, Qiu L and Li Z: Simultaneous
quantification of serum nonesterified and esterified fatty acids as
potential biomarkers to differentiate benign lung diseases from
lung cancer. Sci Rep. 6:342012016. View Article : Google Scholar : PubMed/NCBI
|
16
|
Jia K, Li W, Wang F, Qu H, Qiao Y, Zhou L,
Sun Y, Ma Q and Zhao X: Novel circulating peptide biomarkers for
esophageal squamous cell carcinoma revealed by a magnetic
bead-based MALDI-TOFMS assay. Oncotarget. 7:23569–23580. 2016.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Wang S, Chen X, Luan H, Gao D, Lin S, Cai
Z, Liu J, Liu H and Jiang Y: Matrix-assisted laser
desorption/ionization mass spectrometry imaging of cell cultures
for the lipidomic analysis of potential lipid markers in human
breast cancer invasion. Rapid Commun Mass Spectrom. 30:533–542.
2016. View
Article : Google Scholar : PubMed/NCBI
|
18
|
Kawaguchi-Sakita N, Kaneshiro-Nakagawa K,
Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, Kajihara S, Fujita Y,
Iwamoto S, Tanaka K and Toi M: Serum immunoglobulin G Fc region
N-glycosylation profiling by matrix-assisted laser
desorption/ionization mass spectrometry can distinguish breast
cancer patients from cancer-free controls. Biochem Biophys Res
Commun. 469:1140–1145. 2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Zhao J, Fan YX, Yang Y, Liu DL, Wu K, Wen
FB, Zhang CY, Zhu DY and Zhao S: Identification of potential plasma
biomarkers for esophageal squamous cell carcinoma by a proteomic
method. Int J Clin Exp Pathol. 8:1535–1544. 2015.PubMed/NCBI
|
20
|
Schwacke J, Millar TP, Hammond CE, Saha A,
Hoffman BJ, Romagnuolo J, Hill EG and Smolka AJ: Discrimination of
normal and esophageal cancer plasma proteomes by MALDI-TOF mass
spectrometry. Dig Dis Sci. 60:1645–1654. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Fan NJ, Gao CF and Wang XL: Tubulin beta
chain, filamin A alpha isoform 1, and cytochrome b-c1 complex
subunit 1 as serological diagnostic biomarkers of esophageal
squamous cell carcinoma: A proteomics study. OMICS. 17:215–223.
2013. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhai XH, Yu JK, Lin C, Wang LD and Zheng
S: Combining proteomics, serum biomarkers and bioinformatics to
discriminate between esophageal squamous cell carcinoma and
pre-cancerous lesion. J Zhejiang Univ Sci B. 13:964–971. 2012.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Weiner LM, Surana R and Wang S: Monoclonal
antibodies: Versatile platforms for cancer immunotherapy. Nat Rev
Immunol. 10:317–327. 2010. View
Article : Google Scholar : PubMed/NCBI
|
24
|
Rutkowski MJ, Sughrue ME, Kane AJ, Mills
SA and Parsa AT: Cancer and the complement cascade. Mol Cancer Res.
8:1453–1465. 2010. View Article : Google Scholar : PubMed/NCBI
|
25
|
Sliwkowski MX and Mellman I: Antibody
therapeutics in cancer. Science. 341:1192–1198. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Taylor RP and Lindorfer MA: The role of
complement in mAb-based therapies of cancer. Methods. 65:18–27.
2014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Baig NA, Taylor RP, Lindorfer MA, Church
AK, LaPlant BR, Pettinger AM, Shanafelt TD, Nowakowski GS and Zent
CS: Induced resistance to ofatumumab-mediated cell clearance
mechanisms, including complement-dependent cytotoxicity, in chronic
lymphocytic leukemia. J Immunol. 192:1620–1629. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Markiewski MM, DeAngelis RA, Benencia F,
Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G and
Lambris JD: Modulation of the antitumor immune response by
complement. Nat Immunol. 9:1225–1235. 2008. View Article : Google Scholar : PubMed/NCBI
|
29
|
Khan MA, Assiri AM and Broering DC:
Complement and macrophage crosstalk during process of angiogenesis
in tumor progression. J Biomed Sci. 22:582015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Sayegh ET, Bloch O and Parsa AT:
Complement anaphylatoxins as immune regulators in cancer. Cancer
Med. 3:747–758. 2014. View
Article : Google Scholar : PubMed/NCBI
|
31
|
Denko NC, Fontana LA, Hudson KM, Sutphin
PD, Raychaudhuri S, Altman R and Giaccia AJ: Investigating hypoxic
tumor physiology through gene expression patterns. Oncogene.
22:5907–5914. 2003. View Article : Google Scholar : PubMed/NCBI
|